Larimar Therapeutics aims to file BLA for Nomlabofusp: H.C. Wainwright expects market launch in 2027 and billion-dollar revenue

H.C. Wainwright begins coverage of the Larimar stock with a "Buy" recommendation and a price target of $10 on July 2. The filing of the Biologics License Application (BLA) for the main candidate Nomlabofusp is planned for the end of the year; analysts anticipate an accelerated review process (Priority Review). They expect sales of $47.9 million in the year of potential market launch in 2027, which is projected to rise to over $1.1 billion annually by 2040. The business model: Cell-penetrating peptides for rare diseases Larimar Therapeutics...